Join us for “Pathophysiology and Pathomechanisms of the Most Common Inherited Peripheral Neuropathies: CMT1A and HNPP” a keynote presentation by Dr. Kathryn Moss, School of Medicine – Neurology, PM & R MizzouForward faculty candidate.  Dr. Moss will present on her research for approximately 40-minutes with a 20-minute question and answer session to follow.

Dr. Kathryn Moss received her BS degree in Cellular and Molecular Biology from the University of Michigan and earned her PhD in Biochemistry, Cell, and Developmental Biology at Emory University School of Medicine. Her dissertation research identified molecular mechanisms of mRNA regulation in neurological disease models. Dr. Moss is currently a postdoctoral fellow in the laboratory of Dr. Ahmet Höke at Johns Hopkins University School of Medicine. Her research is focused on understanding the pathogenesis of the two most common inherited peripheral neuropathies: Charcot-Marie-Tooth disease Type 1A (CMT1A) and Hereditary Neuropathy with Liability to Pressure Palsies (HNPP). She working to understand mechanisms of myelin dysfunction and secondary axon degeneration in CMT1A and HNPP as well as the physiological function of PMP22 in myelin. Dr. Moss’ goal is to contribute to therapy development for CMT1A and HNPP by identifying novel approaches to rescue myelin deficits and informing when potential therapies will be most effective. Dr. Moss’ research endeavors are enhanced by her involvement in the Peripheral Nerve Society where she serves as Chair of the Junior Committee. 

Both increased and decreased dosage of the Peripheral Myelin Protein 22 (PMP22) gene cause dysmyelinating peripheral neuropathy, indicating that precise PMP22 expression is required for normal peripheral nerve myelination. PMP22 duplication causes Charcot-Marie-Tooth Disease Type 1A (CMT1A) and PMP22 deletion causes Hereditary Neuropathy with Liability to Pressure Palsies (HNPP). CMT1A and HNPP are the most common inherited peripheral neuropathies and although both diseases dramatically impact patient quality of life and burden the healthcare system, only supportive treatments are currently available to patients. Thus, there is a critical need to understand the pathophysiology and pathomechanisms of CMT1A and HNPP to improve their therapeutic potential.

You can access Dr. Moss’ CV via OneDrive here:

 CV_K Moss.pdf (University log in required to access)

After the keynote, please provide candidate feedback with our brief survey.